Hawaii 2024 Regular Session

Hawaii Senate Bill SB446 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.B. NO. 446 THIRTY-SECOND LEGISLATURE, 2023 S.D. 1 STATE OF HAWAII A BILL FOR AN ACT RELATING TO PRESCRIPTION DIGITAL THERAPEUTICS. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	THE SENATE S.B. NO. 446
4	4	THIRTY-SECOND LEGISLATURE, 2023 S.D. 1
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.B. NO.
10	10
11	11	446
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15	S.D. 1
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	RELATING TO PRESCRIPTION DIGITAL THERAPEUTICS.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. (a) The department of health shall conduct a study to determine the feasibility of implementing a pilot program to integrate innovative, evidence-based prescription digital therapeutics approved by the federal Food and Drug Administration in outpatient treatment programs for persons with substance use disorder or opioid use disorder within the State. The study shall consider: (1) Any potential short-term and long-term financial effects on the State for the pilot program, which shall include: (A) The demographics and needs of persons with substance use disorder or opioid use disorder within the State; (B) The costs and benefits of integrating different approved prescription digital therapeutic products into treatment programs in the State, including any security and privacy considerations; and (C) How various governmental entities can best help provide medical assistance coverage of the approved prescription digital therapeutic products for the treatment of substance use disorders and opioid use disorders, including any immediate and ongoing availability of federal funds; (2) Any oversight and regulatory requirements necessary to implement the pilot program, including any potential hurdles and strategies to address the potential hurdles; (3) Any effect of the pilot program on relevant existing health care providers and health care organizations, programs, and agencies; (4) Any other beneficial alternative options; (5) Which agency or agencies are best equipped to administer the pilot program, including how the pilot program should be structured; (6) Which facility or facilities in the State are best suited to implement the pilot program; (7) Which approved prescription digital therapeutic products best fit the needs of persons with substance use disorder or opioid use disorder in the State; (8) How to evaluate the outcomes of the pilot program, including preferred frameworks to gauge the impact of the approved prescription digital therapeutic products, especially when used in conjunction with other treatments and therapies; and (9) Other considerations necessary to help health care decision-makers accurately anticipate the impact of approved prescription digital therapeutic products on the overall delivery of health care in the State. (b) The department of health shall submit a report of its findings and recommendations from the study, including any proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2024. SECTION 2. This Act shall take effect on December 31, 2050.
48	48
49	49	SECTION 1. (a) The department of health shall conduct a study to determine the feasibility of implementing a pilot program to integrate innovative, evidence-based prescription digital therapeutics approved by the federal Food and Drug Administration in outpatient treatment programs for persons with substance use disorder or opioid use disorder within the State. The study shall consider:
50	50
51	51	(1) Any potential short-term and long-term financial effects on the State for the pilot program, which shall include:
52	52
53	53	(A) The demographics and needs of persons with substance use disorder or opioid use disorder within the State;
54	54
55	55	(B) The costs and benefits of integrating different approved prescription digital therapeutic products into treatment programs in the State, including any security and privacy considerations; and
56	56
57	57	(C) How various governmental entities can best help provide medical assistance coverage of the approved prescription digital therapeutic products for the treatment of substance use disorders and opioid use disorders, including any immediate and ongoing availability of federal funds;
58	58
59	59	(2) Any oversight and regulatory requirements necessary to implement the pilot program, including any potential hurdles and strategies to address the potential hurdles;
60	60
61	61	(3) Any effect of the pilot program on relevant existing health care providers and health care organizations, programs, and agencies;
62	62
63	63	(4) Any other beneficial alternative options;
64	64
65	65	(5) Which agency or agencies are best equipped to administer the pilot program, including how the pilot program should be structured;
66	66
67	67	(6) Which facility or facilities in the State are best suited to implement the pilot program;
68	68
69	69	(7) Which approved prescription digital therapeutic products best fit the needs of persons with substance use disorder or opioid use disorder in the State;
70	70
71	71	(8) How to evaluate the outcomes of the pilot program, including preferred frameworks to gauge the impact of the approved prescription digital therapeutic products, especially when used in conjunction with other treatments and therapies; and
72	72
73	73	(9) Other considerations necessary to help health care decision-makers accurately anticipate the impact of approved prescription digital therapeutic products on the overall delivery of health care in the State.
74	74
75	75	(b) The department of health shall submit a report of its findings and recommendations from the study, including any proposed legislation, to the legislature no later than twenty days prior to the convening of the regular session of 2024.
76	76
77	77	SECTION 2. This Act shall take effect on December 31, 2050.
78	78
79	79	Report Title: Department of Health; Feasibility Study; Pilot Program; Prescription Digital Therapeutics; Outpatient Treatment; Substance Use Disorder; Opioid Use Disorder Description: Requires the Department of Health to conduct a study to determine the feasibility of implementing a pilot program to integrate prescription digital therapeutic products approved by the federal Food and Drug Administration in outpatient treatment programs for persons with substance use disorder and persons with opioid use disorder in the State. Requires a report to the Legislature. Effective 12/31/2050. (SD1) The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
80	80
81	81
82	82
83	83
84	84
85	85	Report Title:
86	86
87	87	Department of Health; Feasibility Study; Pilot Program; Prescription Digital Therapeutics; Outpatient Treatment; Substance Use Disorder; Opioid Use Disorder
88	88
89	89
90	90
91	91	Description:
92	92
93	93	Requires the Department of Health to conduct a study to determine the feasibility of implementing a pilot program to integrate prescription digital therapeutic products approved by the federal Food and Drug Administration in outpatient treatment programs for persons with substance use disorder and persons with opioid use disorder in the State. Requires a report to the Legislature. Effective 12/31/2050. (SD1)
94	94
95	95
96	96
97	97
98	98
99	99
100	100
101	101	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.